Asthma and COPD Drugs Market - Top Companies and Manufacturers

  • Report ID: 4116
  • Published Date: May 22, 2024
  • Report Format: PDF, PPT

Companies dominating the Asthma and COPD Drugs Landscape

top-features-companies
    • GlaxoSmithKline plc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • AstraZeneca
    • Boehringer Ingelheim International GmbH
    • F. Hoffmann-La Roche Ltd.
    • Novartis AG
    • Sanofi
    • CHIESI Farmaceutici S.p.A.
    • Teva Pharmaceutical Industries Ltd.
    • Merck & Co., Inc.
    • Abbott

Browse Key Market Insights with Data Illustration:

In the News

  • Dignity Health, and Propeller Health announced that they have integrated Propeller’s platform into Dignity Health’s electronic health record (EHR) system, which is fully implemented in seven communities served by Dignity Health physicians and clinics in Arizona and California.
  • True Corporation along with partners, Easy Asthma & COPD Clinics (EACC), a network of respiratory disease treatment clinics, and GlaxoSmithKline Thailand (GSK), a researcher and developer of innovative drugs and vaccines, launched “Telehealth Together” project to take care of patients suffering from respiratory diseases using True's health intelligent healthcare platform for telehealth services.

Author Credits:  Radhika Pawar


  • Report ID: 4116
  • Published Date: May 22, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of asthma and copd drugs is evaluated at USD 40.1 Billion.

The asthma and COPD drugs market size was over USD 37 Billion in 2023 and is anticipated to exceed USD 97.9 Billion by the end of 2036, witnessing over 7.8% CAGR during the forecast period i.e., between 2024-2036. High prevalence and incidence of asthma and COPD, decreasing environmental air quality, and the presence of harmful gases and particles are the major factors driving the market growth.

North American industry will hold the largest share by 2036, as growing healthcare infrastructure in the region is able to provide the required treatment to the patients.

GlaxoSmithKline plc., AstraZeneca, Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd., Novartis AG, Sanofi, CHIESI Farmaceutici S.p.A., Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., Abbott
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying